26 related articles for article (PubMed ID: 2720665)
1. Vitamin K epoxide reductase regulation of androgen receptor activity.
Tew BY; Hong TB; Otto-Duessel M; Elix C; Castro E; He M; Wu X; Pal SK; Kalkum M; Jones JO
Oncotarget; 2017 Feb; 8(8):13818-13831. PubMed ID: 28099154
[TBL] [Abstract][Full Text] [Related]
2. Targeting hyaluronic acid family for cancer chemoprevention and therapy.
Lokeshwar VB; Mirza S; Jordan A
Adv Cancer Res; 2014; 123():35-65. PubMed ID: 25081525
[TBL] [Abstract][Full Text] [Related]
3. Dietary supplement hymecromone and sorafenib: a novel combination for the control of renal cell carcinoma.
Benitez A; Yates TJ; Shamaldevi N; Bowen T; Lokeshwar VB
J Urol; 2013 Jul; 190(1):285-90. PubMed ID: 23228386
[TBL] [Abstract][Full Text] [Related]
4. Antitumor activity of hyaluronic acid synthesis inhibitor 4-methylumbelliferone in prostate cancer cells.
Lokeshwar VB; Lopez LE; Munoz D; Chi A; Shirodkar SP; Lokeshwar SD; Escudero DO; Dhir N; Altman N
Cancer Res; 2010 Apr; 70(7):2613-23. PubMed ID: 20332231
[TBL] [Abstract][Full Text] [Related]
5. Synthesis, characterization, and cytotoxic activity of new lanthanum(III) complexes of bis-coumarins.
Kostova I; Momekov G; Tzanova T; Karaivanova M
Bioinorg Chem Appl; 2006; 2006():25651. PubMed ID: 17497005
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the antitumour activity of coumarin in prostate cancer models.
Maucher A; Kager M; von Angerer E
J Cancer Res Clin Oncol; 1993; 119(3):150-4. PubMed ID: 8418087
[TBL] [Abstract][Full Text] [Related]
7. Antitumour activity of coumarin in prostate and mammary cancer models.
von Angerer E; Kager M; Maucher A
J Cancer Res Clin Oncol; 1994; 120 Suppl():S14-6. PubMed ID: 8132695
[TBL] [Abstract][Full Text] [Related]
8. Prostate cancer. Growth kinetics.
Alison MR; Wright NA
Recent Results Cancer Res; 1981; 78():29-43. PubMed ID: 6168012
[No Abstract] [Full Text] [Related]
9. Coumarin (1,2-benzopyrone) for the treatment of prostatic carcinoma.
Mohler JL; Williams BT; Thompson IM; Marshall ME
J Cancer Res Clin Oncol; 1994; 120 Suppl():S35-8. PubMed ID: 8132702
[TBL] [Abstract][Full Text] [Related]
10. Effect of coumarin on the normal rat prostate and on the R-3327H prostatic adenocarcinoma.
Omarbasha B; Fair WR; Heston WD
Cancer Res; 1989 Jun; 49(11):3045-9. PubMed ID: 2720665
[TBL] [Abstract][Full Text] [Related]
11. Comparative antitumor effects of hormonal ablation, estrogen agonist, estrogen cytotoxic derivative, and antiestrogen in the PAIII rat prostatic adenocarcinoma.
Neubauer BL; Best KL; Goode RL; Heiman ML; Hoover DM; Robertson DW; Sarosdy MF; Shaar CJ; Tanzer LR; Merriman RL
Cancer Res; 1992 Sep; 52(17):4663-71. PubMed ID: 1511432
[TBL] [Abstract][Full Text] [Related]
12. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers.
Xu Y; Dalrymple SL; Becker RE; Denmeade SR; Isaacs JT
Clin Cancer Res; 2006 Jul; 12(13):4072-9. PubMed ID: 16818707
[TBL] [Abstract][Full Text] [Related]
13. Rapid suppression of plasma testosterone levels and tumor growth in the dunning rat model treated with degarelix, a new gonadotropin-releasing hormone antagonist.
Princivalle M; Broqua P; White R; Meyer J; Mayer G; Elliott L; Bjarnason K; Haigh R; Yea C
J Pharmacol Exp Ther; 2007 Mar; 320(3):1113-8. PubMed ID: 17179469
[TBL] [Abstract][Full Text] [Related]
14. Prostate cancer chemoprevention by green tea: in vitro and in vivo inhibition of testosterone-mediated induction of ornithine decarboxylase.
Gupta S; Ahmad N; Mohan RR; Husain MM; Mukhtar H
Cancer Res; 1999 May; 59(9):2115-20. PubMed ID: 10232597
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
